Patrick O. Hanafin

Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing

Brian Jermain, Patrick O. Hanafin, Yanguang Cao et al. · Journal of Pharmaceutical Sciences · 2020 · 46 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients

Patrick O. Hanafin, Roger L. Nation, Marc H. Scheetz et al. · CPT Pharmacometrics & Systems Pharmacology · 2021 · 33 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A mechanism‐based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID‐19 treatment in humans

Patrick O. Hanafin, Brian Jermain, Anthony J. Hickey et al. · CPT Pharmacometrics & Systems Pharmacology · 2020 · 29 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients

Patrick O. Hanafin, Andrea Lay‐Hoon Kwa, Alexandre Prehn Zavascki et al. · Clinical Microbiology and Infection · 2023 · 24 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis

Patrick O. Hanafin, Isabelle Sermet‐Gaudelus, Matthias Griese et al. · Frontiers in Pharmacology · 2021 · 22 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15